已接種疫苗人士感染Omicron後對其他變異株也可產生抗體反應
格隆匯5月17日丨由香港大學及中文大學醫學院聯合發表的一項研究發現,相比未接種疫苗的人士,已接種疫苗人士在感染新型冠狀病毒變異株Omicron後,能對不同的新冠病毒變異株產生更強烈和更廣泛的中和病毒抗體反應;反映未接種疫苗人士即使曾經感染新冠病毒,亦須接種新冠疫苗。研究結果顯示,已完成接種疫苗人士在經歷Omicron病毒株突破性感染時,能夠產生更強烈及有效的抗體反應,比從未接種新冠疫苗的人士高出6倍或以上。更重要的是,已接種疫苗人士的中和病毒抗體反應更廣泛,對其他須關注的新冠變異株如Beta和Delta病毒株也可產生抗體反應。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.